Cantor Fitzgerald Weighs in on Insmed FY2025 Earnings

Insmed Incorporated (NASDAQ:INSM - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Insmed in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim anticipates that the biopharmaceutical company will post earnings per share of ($4.65) for the year. The consensus estimate for Insmed's current full-year earnings is ($5.44) per share.

INSM has been the subject of a number of other reports. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Wednesday, October 9th. Truist Financial reissued a "buy" rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a research note on Friday, November 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Insmed Trading Up 1.8 %

Shares of Insmed stock traded up $1.36 during trading hours on Wednesday, hitting $78.11. The company's stock had a trading volume of 900,272 shares, compared to its average volume of 2,084,735. The stock has a market cap of $13.97 billion, a price-to-earnings ratio of -14.08 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed has a twelve month low of $21.92 and a twelve month high of $80.53. The firm has a fifty day moving average of $71.19 and a 200-day moving average of $72.72.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. During the same quarter last year, the firm posted ($1.10) earnings per share. The company's revenue was up 18.1% on a year-over-year basis.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the transaction, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Martina M.D. Flammer sold 6,172 shares of the business's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the sale, the insider now directly owns 101,549 shares in the company, valued at approximately $6,462,578.36. The trade was a 5.73 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 104,740 shares of company stock valued at $7,161,294. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. lifted its holdings in shares of Insmed by 211.9% during the second quarter. Envestnet Asset Management Inc. now owns 175,464 shares of the biopharmaceutical company's stock valued at $11,756,000 after purchasing an additional 119,214 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Insmed in the second quarter worth about $810,000. Amalgamated Bank raised its holdings in shares of Insmed by 15.2% during the second quarter. Amalgamated Bank now owns 5,327 shares of the biopharmaceutical company's stock valued at $357,000 after acquiring an additional 701 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Insmed in the 2nd quarter valued at approximately $358,000. Finally, Hsbc Holdings PLC boosted its stake in Insmed by 45.6% in the 2nd quarter. Hsbc Holdings PLC now owns 23,151 shares of the biopharmaceutical company's stock worth $1,538,000 after purchasing an additional 7,255 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.